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Amylin in the periphery II: An updated mini-review
Abstract
Amylin is a polypeptide that is cosecreted with insulin from the beta cells of the pancreas. Therefore, in
states of diabetes in which the beta-cell mass is largely depleted or dysfunctional, insulin and amylin
secretion are also lost or dysregulated. While the soluble monomeric form of amylin acts as a hormone
that alters physiological responses related to feeding and acts as a specific growth factor, there has been
renewed interest in the less-soluble oligomeric and insoluble polymeric forms of human (also monkey
and cat) amylin that may contribute to the establishment of a pathophysiological pathway to overt
diabetes. With this discovery has grown the hope of minimizing, with appropriate therapy, these toxic
forms to preserve the functional (c) not-cell mass. Human beta cells may also be more vulnerable to
these forms and one risk factor, a higher fat diet, may promote toxic forms. The generation and utilities
of transgenic rodent models, which express enhanced levels of human amylin, have been accompanied
by strategies that may lead to the reduction of toxic forms and associated risk factors. The successful
definition and faithful expression of the physiological receptors (and complexes) for amylin that may
differ for each target organ is an important development in the field of amylin research generally.
Besides the heuristic value for the understanding of the molecular biology of receptors, the opportunity
to screen and identify nonpeptide analogues that bind the physiological receptors has important
implications for biomedicine and clinical practice in relation to treatments for diabetic complications,
bone diseases, and eating disorders. In particular, in their capacities to mimic the effects of amylin as a
growth factor, amylin analogues may prove useful in the stimulation of beta-cell mass (in conjunction
with other factors), reduce the activity of the osteoclast population, and stimulate the regeneration of
proximal tubules following toxic insult (and thus avoid the development of renal insufficiency).
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This Revised Review is a revision of the review article published, Vol. 3, 2003 
Amylin is a polypeptide that is cosecreted with insulin from the β cells of the pancreas. 
Therefore, in states of diabetes in which the β-cell mass is largely depleted or 
dysfunctional, insulin and amylin secretion are also lost or dysregulated. 
While the soluble monomeric form of amylin acts as a hormone that alters 
physiological responses related to feeding and acts as a specific growth factor, there has 
been renewed interest in the less-soluble oligomeric and insoluble polymeric forms of 
human (also monkey and cat) amylin that may contribute to the establishment of a 
pathophysiological pathway to overt diabetes. With this discovery has grown the hope of 
minimizing, with appropriate therapy, these toxic forms to preserve the functional ß-cell 
mass. Human β cells may also be more vulnerable to these forms and one risk factor, a 
higher fat diet, may promote toxic forms. The generation and utilities of transgenic 
rodent models, which express enhanced levels of human amylin, have been 
accompanied by strategies that may lead to the reduction of toxic forms and associated 
risk factors. 
The successful definition and faithful expression of the physiological receptors (and 
complexes) for amylin that may differ for each target organ is an important development 
in the field of amylin research generally. Besides the heuristic value for the 
understanding of the molecular biology of receptors, the opportunity to screen and 
identify nonpeptide analogues that bind the physiological receptors has important 
implications for biomedicine and clinical practice in relation to treatments for diabetic 
complications, bone diseases, and eating disorders. In particular, in their capacities to 
mimic the effects of amylin as a growth factor, amylin analogues may prove useful in the 
stimulation of β-cell mass (in conjunction with other factors), reduce the activity of the 
osteoclast population, and stimulate the regeneration of proximal tubules following toxic 
insult (and thus avoid the development of renal insufficiency). 
KEYWORDS: amylin, hormone, growth factor, amyloidogenesis, beta-cell integrity, 
diabetes,brain, feeding, kidney, receptors 
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INTRODUCTION 
Amylin, discovered in 1987[1,2], is a hormone cosecreted with insulin by the β cells of the pancreas and, 
therefore, has been considered a partner peptide in the etiology of diabetes-associated complications and 
related conditions. This mini-review is an update, based on a mini-review published 4 years ago[3], and 
focuses principally on current issues that challenge researchers in the field. There are several 
comprehensive reviews that include a more detailed assessment of our current knowledge of the hormonal 
effects and biochemistry of amylin[3,4,5,6,7,8]. It is true to add that the recent approval for the 
administration of amylin analogues to human diabetic subjects has sparked a good deal of fresh interest in 
the issues of “amylin in the periphery”. 
One of the key questions addressed is the role played by different forms of human islet amylin in the 
etiology of type II diabetes and the utility of transgenic rodent models to address that research question. A 
future outcome could be the selection of candidate compounds that reduce the deleterious effects or 
formation of the toxic form. Could these compounds be useful as preventative treatments for potential 
diabetic subjects to stave off overt diabetes? 
In view of the potential role of monomeric amylin and other peptides to act in synergy as growth 
factors, particularly in the context of the maintenance of β-cell mass, bone density, and kidney function, can 
high-affinity, nonpeptide analogues be screened and cocktails assembled that could promote healthy tissues? 
The effect of amylin on functions related to feeding (including gut motility), in particular satiation 
used in the sense of control of meal size, is mediated by the brain and is considered here in the context of 
the actions of several peptides that are components of the gut-brain axis. Scientists would like to 
understand the peptides’ actions so that related drugs might be developed to ameliorate eating disorders, 
such as obesity. 
The final issue presented in detail is the unresolved issue of the identity of amylin receptors. Clearly, 
our knowledge of the molecular components of amylin receptor(s) in each tissue will be important to 
deduce for other than heuristic reasons. It is likely that amylin receptors differ in the central nervous 
system (CNS), kidney, endocrine pancreas, and bone. The question here is whether these molecular 
entities can be reassembled in a form that is useful for the identification of nonpeptide agonists and 
antagonists for the amelioration of feeding disorders and complications associated with diabetes. 
AMYLOIDOGENESIS AND β-CELL RESPONSES 
There are several biological issues that need to be considered before the strong correlation between 
amyloid formation and the etiology of diabetes (type II) can be understood. Some of these issues have 
been discussed in the previous mini-review[3]. 
First, in species that express forms of amylin prone to amyloidogenesis, the percent of diabetics (type 
II) with amyloid plaque found in the pancreas is very high, reaching 90–100% in humans, cats, and 
macaque monkeys, and islet amyloidosis in feline diabetes is associated with a mean loss of β-cell mass 
of 50%[9]. In this context, it has recently been proposed that an event prior to the process of islet amyloid 
formation seems to be more toxic to β-cells than the end result of the amyloid plaque (discussed below).  
Furthermore β cells from different species seem to differ in their vulnerability to different insults 
including toxic amyloid entities[10]. Other factors that may lead to net β-cell death and consequent β-cell 
insufficiency include oxidative damage, changes in islet blood flow, cytokine toxicity, and certain dietary 
influences[11,12]. 
TRANSGENIC RODENT MODELS THAT EXPRESS HUMAN AMYLIN 
It is evident that not all species that express and secrete amylin form islet amyloid plaques. Early work 
demonstrated that humans, primates, and cats form islet amyloid associated with diabetes, while rats and 
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mice were devoid of islet amyloid formation. This species difference was due to an amyloidogenic 
sequence in amylin necessary for the formation of amyloid plaques[13]. Since rodents did not form islet 
amyloid, a number of research groups generated transgenic mice that expressed the human amylin gene in 
islet β cells, but the initial studies on these mouse transgenic models (discussed in [3]) were 
disappointing, as no islet amyloid could be detected[14,15,16,17].  
Various strategies were then considered to increase amylin secretion including breeding to 
homozygosity and the induction of insulin resistance with nicotinic acid or glucocorticoids, but islet 
amyloid was still not detected, indicating that hypersecretion of amylin alone is not sufficient for the 
formation of amyloid[10,18]. It was believed that other factors might be required for islet amyloid 
formation. In retrospect, this should not have been a surprise, since humans express and secrete 
amyloidogenic amylin that in most of us does not normally result in amyloid, unless diabetes intervenes. 
It was by chance with the relocation of one of the human amylin transgenic mouse lines to another 
animal facility that resulted in the formation of histological islet amyloid plaques, similar to those 
observed in humans with type II diabetes[18]. This phenomenon appeared to be linked to an increase in 
dietary fat, which was subsequently confirmed in this[19] and another transgenic model[20].  
Subsequent studies have shown that obesity induced by expression of the leptin mutation (ob/ob)[21], 
or ectopic and ubiquitous expression of agouti (Avy/a)[22,23], resulted in islet amyloid formation 
associated with hyperglycemia. In fact, the latter study suggested that it was an event prior to islet 
amyloid formation and possibly intracellular, soluble amylin oligomers that were more toxic to islet β 
cells than the amyloid plaque[23]. The idea that oligomeric amylin is toxic is a recent development in the 
field that has been supported by research using a new model, the transgenic human amylin (HIP) 
rat[24,25]. This HIP rat is characterized by the development of diabetes due to islet β-cell apoptosis in the 
absence of islet amyloid, leading the authors to conclude that intracellular amylin oligomers may be 
responsible for the net death of β cells[24,26]. Further in vitro studies support the role of amylin 
oligomers as the primary cause of β-cell death via activation of the apoptotic pathway[27]. 
OTHER FACTORS MAY ALSO MAKE MAJOR CONTRIBUTIONS TO β-CELL 
SURVIVAL AND/OR THE GENERATION OF AMYLIN-RELATED TOXICITY 
The generation of toxic forms of amylin may be potentiated in the context of other pathophysiological 
events associated with pancreatic islets. 
The renin-angiotensin system (RAS) has been shown to have several functions including inhibition of 
proliferation, induction of apoptosis, and generation of reactive oxygen species that may be deleterious to 
cell function[28]. Recent studies have shown that the components of the RAS (angiotensinogen, AT-1, 
and AT-2 receptors) are present in the endocrine pancreas[29,30]. We have shown that components of the 
RAS are up-regulated in pancreatic islets of the Zucker fat (ZDF) rat and are associated with intraislet 
fibrosis, apoptosis, and oxidative stress[31]. Pretreatment of ZDF rats with the angiotensin converting 
enzyme inhibitors perindopril or irbesartan decreased the components of the RAS, reduced islet 
fibrogenesis and apoptosis, and significantly improved glucose-mediated insulin secretion[31]. The 
impact of such regimens and altered islet blood flow on the generation of toxic forms of amylin are yet to 
be described. 
THE EFFECTS OF PERIPHERAL AMYLIN ON THE BRAIN AND THE GUT-BRAIN 
AXIS 
The effects of peripheral amylin on the CNS have been described in terms of anorectic effects that alter 
physiological responses to feeding and putative dipsogenic effects that alter thirst and, therefore, drinking 
behavior[32]. The latter dipsogenic effects were exerted through neural pathways present in the 
subfornical organ (SFO) of the circumventricular organs (CVOs). Brain centers often activated in 
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association with feeding, namely the lateral hypothalamic area (LHA) and the ventromedial hypothalamus 
(VMH), were also identified using functional MRI while drinking water[33]. 
In contrast to the limited description of the dipsogenic effects, there is now a large body of research 
on the effects of amylin in relation to feeding behavior including the well-documented promotion of 
satiation (that determines meal size), the inhibition of gastric emptying, and the control of glucagon 
secretion. Here the effects of amylin on satiation are introduced within the broader context of the gut-
brain axis.  
The original term “gut-brain” axis was coined in the late 1970s and resulted from discoveries that 
identified many of the gut peptides within the brain[34], previously considered quite separate 
compartments. Furthermore, the blood-brain barrier was considered an impenetrable barrier with regions 
of higher permeability typically only seen in certain anatomical locations such as the CVOs.  
EMERGING VIEWS OF THE “GUT-BRAIN” AXIS AND THE BLOOD-BRAIN 
BARRIER 
More recently, the blood-brain barrier is emerging as a regulatory interface for many molecules including 
hormones and larger polypeptides[34]. In order to cross the blood-brain barrier, there are specific 
transporters (e.g., insulin, leptin), the activities of which may be modified and regulated by direct 
interactions with other serum proteins[35]. The activities of the specific transporters may be modified 
according to requirements to maintain the energy balance[36], the metabolic requirements of the CNS, 
activities within serum, and pathophysiological states, such as obesity and diabetes[37].  
The full extent of the brain and neural networks that integrate feeding responses are part of a more 
general physiological concept of control of energy homeostasis, the neural components of which have yet 
to be defined fully. The systems that might be integrated at this level include conscious and conditioned 
responses that give rise to feeding behavior, control of energy reserves, circadian rhythms, sleep/wake 
cycles, and others. 
An important site for the actions of amylin that alter feeding responses resides in the area postrema 
(AP) where calcitonin receptor (CTR)–positive neurons[38] are activated via a cGMP-dependent 
mechanism[39]. Surgical ablation of the AP resulted in the negation of the effects of salmon calcitonin 
(sCT) and amylin[40], and these actions have also been inhibited by the peptide antagonist of amylin or 
sCT binding, AC 187. 
Amylin may act in synergy with other peptides of the gut-brain axis, such as cholecystokinin 
(CCK)[41,42,43], and such events may vary the amplitude of the response to amylin throughout the 
postprandial period.  
Because of these effects of amylin that alter the feeding behavior, and in particular satiation that 
determines meal size, amylin analogues in combination with other components of the gut-brain axis are 
regarded as potential therapies for serious conditions related to obesity and possibly other eating 
disorders[6]. 
The brain centers that are activated following amylin actions at the AP have been described and 
include the nucleus of the solitary tract (NTS) and the lateral parabrachial nucleus (PBN), regions that 
have abundant CTR-positive neurons[38] (see also Figs. 1 and 2). 
AMYLIN AS A GROWTH FACTOR 
Amylin mRNA transcripts (PJW, unpublished data) and protein[44,45] are expressed early in the latter 
half of gestation starting at embryo day 11/12 in the rat pancreatic diverticulum where amylin is 
expressed by P-cells[46]. These observations suggest that any function associated with the early fetal 
expression of this peptide may involve a role for amylin as a growth factor. 
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FIGURE 1. An example of CTR-positive neurons in the rat hindbrain that 
appear to form a network. Networks of calcitonin receptor (CTR)–positive 
neurons are often found[38] in key structures associated with energy 
homeostasis and feeding behavior including the NTS, paraventricular nucleus 
(PVN), lateral hypothalamic area (LHA), arcuate nucleus, as well as components 
of the limbic (nucleus accumbens), circadian (suprachiasmatic nucleus), and 
other systems (locus coeruleus). The relationship between CTR-positive neural 
networks and particular physiological functions has not yet been described.  
 
FIGURE 2. Cartoon of the neural and humoral relationship between the CNS and the endocrine 
pancreas. Abbreviations are area postrema (AP), nucleus of the solitary tract (NTS), parabrachial 
nucleus (PBN), lateral hypothalamic area (LHA), perifornical area (PFA), paraventricular nucleus 
(PVN), arcuate nucleus (ARC), neuropeptide Y (NPY). 
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Pancreatic Islets 
Monomeric amylin has been found to be a growth factor for isolated fetal β cells[48]. This follows 
previous descriptions of its effect on cells involved in bone metabolism and primary cultures of renal 
proximal tubular epithelial cells[49,50,51]. Furthermore, there is support for these data in vivo, in the 
observation that there is a large reduction in the β-cell mass measured in the AMY-/- diploid strain 
compared to wild-type controls[3]. 
These findings probably reflect the potential of monomeric amylin and it is likely that amylin acts in 
synergy with other growth factors such as somatostatin[52] by inducing proliferation of precursors of β 
cells and/or acting as a survival factor to improve the viability of adult β cells. 
To understand the potential of monomeric amylin to act as a growth and/or survival factor, further 
research needs to be undertaken in the context of other events such as the role of cytokines such as IL-
1[53], nitric oxide production[54], and the maintenance of islet blood flow.  
Renal Proximal Tubular Epithelial Cells 
Amylin is also a potent proliferation factor both during the development of proximal tubules[55] and in 
the proliferation of adult epithelial cells[56]. The relevance of this action of amylin as a putative growth 
factor in vivo is further emphasized by the finding that amylin is expressed in the proximal tubules of the 
developing kidney. This occurs prior to vascularization of the rat kidney with peak levels of amylin 
mRNA at postnatal day 5 (PN5), some 200-fold higher than found in adult kidney[3]. This event is tightly 
regulated, a characteristic of the precise events that regulate growth factors during organogenesis. 
The identification of the factors that control this tight regulation of expression of amylin may prove to 
be important later in pathogenic processes such as the development of renal complications associated with 
diabetes and renal regeneration following toxic or other insults. 
Osteoblasts and Osteoclast Differentiation 
Research into the potential effects of amylin on bone density followed the observation that osteopenia 
was found in a large proportion of diabetic subjects[57,58,59,60]. Indeed, this potential effect of amylin 
was among one of the earliest effects described following its discovery. It was demonstrated subsequently 
that amylin acted as a growth factor in bone for the proliferation of osteoblasts[49,61] and recently in 
osteoclast differentiation[50]. 
More recently, the analyses of amylin and CTR gene-deletion mouse models[62] have demonstrated 
that amylin is a factor that inhibits osteoclastogenesis and, therefore, reduces the rate of osteolysis. In 
diabetics, the rate of bone loss is correspondingly accelerated. 
On the other hand, as found in the CT gene-deletion model[63] and in the CTR+/- haplo-insufficient 
strain[62], there is an increase in the rate of bone formation that seems to contradict previous findings on 
the role of CT/CTR in the activity of osteoclasts. 
Dorsal Root Ganglia (DRG) in the AMY-/- Mouse Model 
Amylin mRNA was detected in the developing DRGs of wild type fetal mice[64]. In addition, in the 
AMY-/- diploid strain the number of neuronal cell bodies in DRGs was depleted until around birth (PJW, 
unpublished observations). Together these observations suggested that any role of amylin as a growth 
factor for neurons in the DRGs was transitory or that it acted as a growth or tropic factor for a subgroup 
of neurons that were replaced in the DRGs around birth by other neuronal populations. 
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The latter may represent the truth since it was discovered that the adult AMY-/- diploid strain was 
deficient in aspects of nociception[65], suggesting permanent misrepresentation of a subgroup of neurons 
in the peripheral nervous system (PNS). Whether this is a mechanism that may help explain the changes 
in the PNS in diabetics has not yet been the subject of published research. 
THE MOLECULAR BIOLOGY OF GROUP B, G PROTEIN-COUPLED RECEPTORS 
(GPCRs) 
Group B GPCRs include the seven transmembrane receptors for calcitonin (CTR), for adrenomedulin 
(AM) and calcitonin gene-related peptide (CGRP; calcitonin receptor-like receptor CRLR or CLR), 
vasoactive intestinal polypeptide/pituitary adenylyl cyclase activating peptide (VPAC1R), glucagon and 
parathyroid hormone (receptors PTHR1 and PTHR2), and several other peptide hormones[66].  
In humans, there are several isoforms of CTR (hCTR), all of which result from gene-splicing events 
from a single CTR gene located on chromosome 7. The best characterized are the insert-minus (hCTRa) 
and insert-plus isoforms (hCTRb), which, in human CTR, includes a 16-amino residue insert towards the 
N-terminal domain of the putative second transmembrane span (span II) of hydrophobic amino residues. 
The isoform that may be regarded as equivalent in rodent (CTR C1b) includes a 31-amino residue 
sequence located after span II.  
In either species, CTRa is the predominant isoform that is expressed by different subsets of cells 
within most tissues. Immunohistochemistry and anti-CTR antibodies have been successfully combined to 
identify these CTR-positive cells in a variety of physiological and pathophysiological states including 
cardiovascular disease and certain cancers (PJW, unpublished data). 
Although the on and off rates for CT binding were similar, there are some clear differences in the 
characteristics of the two isoforms when expressed in the BHK cell line. First, hCTRb is significantly 
impaired in its rate of internalization[67]. Second, hCTRb displays a significantly reduced ability to 
couple to the second messenger enzymes adenylyl cyclase and phospholipase C. Third, stimulation of a 
transient calcium response was observed only with the hCTRa isoform[67]. 
Furthermore, when COS-7 cells were transfected with hCTRa, in contrast to the hCTRb isoform, the 
binding of the potent agonist salmon-CT resulted in retardation of the cell cycle with cells stalled in the 
G2/M phase[68]. A calcitonin response element (Sp1 binding site) was identified in the promoter of the 
human p21WAF1/CIP1 gene encoding a cyclin-dependent kinase inhibitor[69]. 
RECEPTOR ACTIVITY MODIFYING PROTEINS (RAMPs) 
RAMPs interact with many members of the Group B GPCRs and appear to be generally involved in the 
cycling of these GPCRs to and from the plasma membrane destined for several cytoplasmic targets, 
depending on the type of RAMP (1, 2, or 3) heterodimer[70]. 
RAMP 1 combined with CLR results in a high-affinity CGRP receptor that can be inhibited with the 
nonpeptide antagonist BIBN4096BS, a drug developed for the inhibition of CGRP-mediated vasodilation, 
a common cause of migraine. RAMP 2 forms heterodimers with CLR to form the AM R1 receptor. 
RAMP 3 contains a PDZ motif near the C-terminus that is thought to direct the CLR-AM-RAMP3 
complex to the lysozyme compartment for degradation. In this case, the receptor is degraded rather than 
being recycled to the plasma membrane[71]. 
The expression of RAMPs is far broader in tissues than the range of cell types that express CLR or 
CTR and, therefore, it was hypothesized that they may also dimerize with other GPCRs of Group B. In 
fact, it has been reported that RAMPs form heterodimers with VPAC1 receptor and the receptors PTHR1 
and PTHR2[72]. In these instances, the association of RAMPs did not appear to influence binding, but 
rather internalization and recycling to the plasma membrane. 
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THE ROLE OF GPCR RECEPTOR HOMO- AND HETERODIMERIZATION IN THE 
FORMATION OF HIGH-AFFINITY BINDING SITES 
The classical idea that GPCRs function as monomeric entities has been unsettled by the emerging concept 
of GPCR homo- and heterodimerization[73]. Dimerization is a potential mechanism that could provide 
high-affinity binding sites for the list of CT-like peptides[74]. This list includes adrenomedulin-1 and -2, 
amylin, calcitonin, calcitonin gene-related peptides, and CTR-stimulating peptide[75].  
Some of these hypothetical combinations of GPCR dimers may also provide lower-affinity binding 
sites that bind a broader spectrum of CT-like peptides.  
AMYLIN-LIKE RECEPTORS IDENTIFIED IN PHARMACOLOGICAL STUDIES USING 
CELL LINES 
The interaction of RAMPs and CTR to form heterodimers that function as an amylin-like receptor in vitro 
is dependent on the isoform of CTR and the cell line used to express the components following 
transfection[66,76,77]. In COS-7 cells, the expression of hCTRb (in contrast to hCTRa) in conjunction 
with RAMPS resulted in the creation of an amylin-like receptor when [125I]-rat amylin was used as the 
test ligand. On the other hand, in the cell line CHO-P, the coexpression of hCTRa and RAMP 2 resulted 
in the generation of an amylin-like binding site[66,78]. 
The interpretation of these data does not provide a clear idea of what events may contribute to create 
the putative amylin binding site, but does serve to raise several questions that are important to address 
before claims regarding the nature of the binding sites can be resolved. 
First, as mentioned above there was a clear difference in the rates of internalization of hCTRa and 
hCTRb. The “binding” experiments[78] were carried out at 37ºC for 1 h on cells that were probably 
viable, but it is not clear from the data what proportion of the associated radioactive ligand was due to 
surface binding (exchangeable) or uptake. Second, the question arises: with coexpression of RAMPs, are 
there changes in the time-dependent rates of internalization of hCTRa and hCTRb that might influence 
uptake? Third, what effects do RAMPs have on the recruitment of G proteins, the coupling to second 
messenger enzymes, and the rate of phosphorylation/dephosphorylation that might influence the rate of 
recycling of these receptors, and hence the amount of associated radioactivity? 
THE PHYSIOLOGICAL ACTIONS OF AMYLIN IN VIVO AND EXPRESSION OF CTR 
Amylin Binding Sites in the Circumventricular Organs of the Brain 
Within the brain, the AP has been identified at which amylin analogues interact to produce physiological 
responses related to feeding. Furthermore, the SFO has been identified as the region at which amylin and 
related peptides may exert dipsogenic actions[32,79]. 
The local expression in the CNS of cognate mRNAs for components thought to comprise an amylin 
receptor were identified, namely, the CTR C1b isoform and RAMP 2[80] and expression was investigated 
using the technique of in situ hybridization (ISH). It was also reported that c-fos mRNA was expressed in 
SFO neurons in response to the injection (i.p.) of amylin or sCT, supporting the SFO as a functional target 
for these peptides and implicating the expression of amylin receptors. 
The same paper did not find significant evidence for expression of the isoform of CTR, C1b, in the 
AP of the hindbrain. This CVO has been identified as a crucial target for the activities of amylin in 
relation to feeding responses[40]. However, there is strong expression of CTR C1a in this region of the 
AP and NTS[48] that express increased levels of cGMP[39] following injection (i.p.) amylin or sCT, 
which is inhibited by the peptide analogue AC187. 
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The Renal Sites of Amylin Actions 
There are several studies that have focused on the actions of amylin in vivo and the possible involvement 
of CTRs, first in the kidney and second in bone metabolism. 
In rat kidney, high-affinity, G protein-dependent binding sites for amylin were identified both using 
in vitro[81] and in vivo autoradiography[56], and these were localized to proximal tubules within the renal 
cortex. Furthermore, in micropuncture, split drop experiments amylin injected into the peritubular 
capillaries of proximal tubules resulted in stimulation of sodium reabsorption (28%) that was inhibited by 
amiloride, an inhibitor of the sodium/hydrogen exchanger[56]. Together, these studies identified proximal 
tubules of the renal cortex as the site of amylin actions in rat kidney. 
In kidney, there are several independent studies that identify the sites of expression of CTR and [125I]-
salmon CT (sCT) binding sites. Salmon CT is a potent ligand of CTR and agonist of CTR actions that 
stimulates several second messenger systems and intracellular events (see above). CTR expression is 
found using immunohistochemistry, predominantly in the renal medulla[81] in epithelial cells of the distal 
tubules, loops of Henle, and collecting ducts, which is in agreement with earlier binding data that 
demonstrated binding to similar renal structures. The expression of RAMP 3 colocalized with CTR[3]. 
In summary, there is a clear distinction between the renal sites of amylin binding and actions on 
proximal tubules, and the sites of expression of CTR by epithelial cells of distal tubules, loops of Henle, 
and collecting ducts[82].  
Amylin Actions on Cells of Bone (In Vitro) and as Demonstrated in Mouse Genetic 
Models (In Vivo) 
In vitro amylin has been characterized as a positive growth factor for osteoblasts[83] and a negative 
growth factor for osteoclasts[84]. This research provided the first evidence that amylin inhibits the 
terminal differentiation of osteoclasts essential for their activation of bone metabolism.  
Thus, in mice that are wild type (AMY +/+), the rate of terminal differentiation of osteoclasts 
(involving fusion of mononuclear precursors into mature multinucleated osteoclasts) is reduced and bone 
mass is relatively high. In both AMY -/- and the haploid AMY +/- gene deletion mouse models in which 
amylin levels are reduced, bone mass is reduced due to the enhanced numbers and the total activity of 
terminally differentiated osteoclasts. The pathology of bones in this model is similar to the phenotype 
observed in osteoporosis. These actions may also explain the high prevalence of low bone mass among 
type I diabetic subjects[85]. 
In this study, it was noted that in the CTR-/- gene deletion model fetuses died early in utero prior to 
skeletogenesis, presumably because of the important role of CTR and endogenous ligands in development 
of fetal organs[86,87], for instance in CNS[88] and other fetal tissues (PJW, unpublished data) including 
perinatal bone. 
Of importance here, it was noted that in the haploid CTR+/- bone density was greater than in wild 
type and that the bone formation rate (BFR) was 30% higher. The opposite effects on bone histology of 
haploinsufficiency in the AMY+/- and CTR+/- strain represents compelling evidence that amylin does not 
exert its effects via CTR in this case. 
The separation of pathways of action was confirmed in the double AMY+/-, CTR+/- strain since there 
was both an increase in osteoclast numbers and an increase in the BFR. 
One striking event that has yet to be understood in terms of the humoral factors that are involved is 
the acute postprandial decrease in bone resorption[89]. In view of the findings discussed above, one 
candidate might be amylin, perhaps acting in synergy with other hormones that are released in response to 
nutrient intake[89]. 
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THE IMPORTANCE OF AMYLIN RECEPTORS 
Although it has been claimed that the proposed CTR/RAMP heterodimer solves the enigma of the amylin 
receptor[90], the topic is still far from resolved within the context of the physiological roles of amylin 
established so far, and the pharmacological data are enshrouded by the uncertainty of clear interpretation. 
An important step forward in the quest to understand the actions of amylin, and for the translation of 
research on the molecular biology and pharmacology of amylin and its receptors will undoubtedly be the 
characterization of several nonpeptide agonists and antagonists as candidates for human therapies and 
further research on amylin receptors. 
Given the important roles ascribed for amylin and its analogues in the control of the postprandial 
glucose surge in diabetic subjects, satiation, bone formation, and renal development and functions, the 
issue of the molecular identities of amylin receptors (and complexes) is compelling. The final solution 
may well reside in the definition of the active heterodimers of GPCRs that may also vary according to the 
particular tissue (brain, islets, bone, kidney, etc.). 
FUTURE DIRECTIONS OF BIOMEDICAL RESEARCH INTO AMYLIN-RELATED 
TOPICS  
Amylin is expressed and largely conserved in molecular terms in each mammalian species, and without 
doubt plays significant roles related to physiological responses related to feeding and as a trophic factor. 
The latter role is relatively unexplored and may involve organ regeneration in adults following insult or 
provide a mechanism of cellular homeostasis in particular organs that are crucial for the maintenance of 
cellular functions, e.g., in the endocrine functions of the β-cell mass or renal proximal tubules. 
The molecular composition and physiological outputs of amylin receptors will be important to refine, 
primarily for the selection of candidate nonpeptide agonists and antagonists that may aid in the treatment 
of existing diabetic conditions. These may improve postprandial control of glucose, help avoid 
hypoglycemic events, and might be coadministered with insulin. Furthermore, some candidates may have 
properties that reduce bone loss by restricting the numbers of functional osteoclasts particularly relevant 
to diabetic complications and osteopenia. They may also prove useful in the physiological integration of 
exogenous transplanted β cells to restore cellular sufficiency and viability. Finally, it is also possible that 
a cocktail of compounds including amylin analogues may prove vital in the treatment of obesity. 
A further aspect requiring more refined pharmacological definition is the potentially toxic form of 
insoluble human amylin, its putative effects on apoptosis of β cells and maintenance of viable β-cell mass. 
Given the increasing incidence of diabetes (type II) there is a large incentive to discover compounds that 
ameliorate the pathophysiological development of these events that are currently regarded as central to the 
development of overt diabetes. 
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